The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.

By P. Hillmen, N. Young, J. Schubert, R. Brodsky, G. Socié, P. Muus, A. Röth, J. Szer, M. Elebute, R. Nakamura and 10 more. New England Journal of Medicine, 2006

1,140 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Nephrology

View Paper: https://www.semanticscholar.org/paper/405fa716fb01a43ab22ae545908c69d821c2d1d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N. Merle
2. S. Church
3. V. Frémeaux-Bacchi
4. Rémi Noé
5. L. Roumenina
6. L. Halbwachs‐Mecarelli
7. S. Rollins
8. C. Mojcik

Citations in the corpus

• Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (2007, methodology): “TRIUMPH was a double-blind, randomized, placebo-controlled, multicenter, phase 3 tria”
• Complement System Part I – Molecular Mechanisms of Activation and Regulation (2015, background): “Eculizumab showed significant improvement in clinical outcome and has been accepted for treatment of complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH) (327) and aHUS (328, 329) and clinical trials are ongoing for other diseases.”
• Complement System Part II: Role in Immunity (2015, background): “This therapeutic is approved for use in PNH and aHUS and gives excellent results (274, 275).”